Table 1.

Main characteristic of included studies.

First author	Year	No. of patients in the treatment group	No. of patients in the control group	Diagnostic criteria	Intervention	Control	Duration of treatment (days)	Duration of followup (months)
CHD Group [21]	1981	138	138	Not reported	Kangxingeng heji + BM	BM	N/A	N/A
Kou [22]	1983	133	135	WHO criteria	Yiqihuoxue decoction and In + Xuejie powder + BM	BM	N/A	N/A
Chen [23]	1984	112	112	WHO criteria	Yiqihuoxue decoction + Yiqihuoxue In + BM	BM	35	N/A
Liang [24]	1989	74	74	Author defined	Tuoqingyanhu su + BM	BM	N/A	N/A
Xia [25]	1993	23	10	Not reported	Dushen tang + thrombolysis	Thrombolysis	3	N/A
Li [26]	1994	60	64	WHO criteria	Wenyanghuoxue decoction + BM	BM	14	0.1
Li [27]	1994	18	15	WHO criteria	Huangqi In + polarized solution	BM + polarized solution	28	1
Yang [28]	1997	66	80	WHO criteria	Shexiangbaoxin tablets + BM	BM	360	12
Zhang [29]	1998	76	59	WHO criteria	JianXin tablet + BM	BM	30	1
Guo [30]	1999	243	259	WHO criteria	Shenmai In + thrombolysis	Thrombolysis	14	1.25
Li [31]	1999	51	50	WHO criteria	Ligustrazine + compound danshen In + Chinese medicinal formulae + thrombolysis	Thrombolysis	28	1
Zhang [32]	1999	52	47	WHO criteria	Yiqihuoxuetongluo decoction + BM	BM	28	1
Guo [33]	2000	143	159	WHO criteria	Suxiao jiuxin pills + thrombolysis	Thrombolysis	14	1.25
Han [34]	2000	38	44	WHO criteria	Huangqi In + thrombolysis	Thrombolysis	10	1
Li [35]	2000	28	19	WHO criteria	Zhupi decoction + BM	BM	7	0.25
Li QZ (a) [36]*	2000	66	80	WHO criteria	Suxiao jiuxin pills + BM	BM	360	12
Li QZ (b) [36]*	2000	66	72	WHO criteria	Suxiao jiuxin pills + BM	BM + Propranolol	360	12
Lu [37]	2000	21	21	WHO criteria	Shuizhi In + BM	BM	14	0.5
Yin [38]	2000	15	13	WHO criteria	Shenmai In + Herba Erigerontis In + BM + thrombolysis	BM + Thrombolysis	14	N/A
Wu [39]	2001	54	49	WHO criteria	Huangqi In + Dan-Shen In + BM	BM	14	0.75
Bai [40]	2002	62	60	WHO criteria	Shenmai In + BM	BM	14	N/A
Shi [41]	2002	58	56	Author defined	Breviscapinun + BM + thrombolysis	BM + Thrombolysis	20	0.67
Guan [42]	2003	30	30	WHO criteria	Xingding In + BM	BM	15	1
Zhang [43]	2003	45	45	Not reported	Shenfu decoction+Xuefuzhupi decoction + BM	BM	28	N/A
Han [44]	2004	46	52	WHO criteria	Shexiangbaoxin tablets + BM + thrombolysis	BM + Thrombolysis	28	1
Li [45]	2004	32	18	WHO criteria	Shexiangbaoxin tablets + BM + thrombolysis	BM + Thrombolysis + placebo	90	3
Liu [46]	2004	41	96	WHO criteria	Shenmai In + BM	BM	15	N/A
Yang [47]	2004	45	45	Not reported	Huangqi In + thrombolysis	Thrombolysis	7	6
Chen [48]	2005	35	34	Not reported	Huangqi In + thrombolysis	Thrombolysis	10	12
Deng [49]	2005	38	35	Not reported	Xingnaojing In + BM	BM	21	24
He [50]	2005	23	23	Author defined	Kaixin capsule + BM + thrombolysis	BM + thrombolysis	5	0.17
Li [51]	2005	83	83	Not reported	Diaohuangqi In + BM	BM	28	2
Liu [52]*	2005	30	22	WHO criteria	Treatment based on TCM syndrome differentiation + thrombolysis	Thrombolysis	28	1
Miao [53]	2005	64	62	WHO criteria	Shengmai In + BM + thrombolysis	BM + thrombolysis	15	2
Yang [54]	2005	45	45	Criteria from the Chinese Society of Cardiology	Shexiangboxin tablets + BM	BM	N/A	3
Ding [55]	2006	15	15	WHO criteria	Shengmai In + BM	BM	N/A	N/A
Du (a)[56]*	2006	1364	1371	Not reported	Xuezhikang capsules + BM	BM + placebo	N/A	84
Du (b) [56]*	2006	1070	1065	Not reported	Xuezhikang capsules + BM	BM + placebo	1440	48
Li [57]	2006	31	32	Guideline from the European Society of Cardiology	Shenfu In + BM	BM	14	N/A
Ma [58]	2006	25	25	Criteria from the Chinese Society of Cardiology	Yuxingeng decoction + BM	BM	28	1
Qi [59]	2006	48	46	WHO criteria	Tanshinone II A sulfoacid In + BM + thrombolysis + PCI	BM + thrombolysis + PCI	14	0.5
Shen [60]	2006	83	82	Author defined	Shenfu In + BM	BM	N/A	0.25
Wang [61]	2006	228	162	WHO criteria	Shenmai In + BM	BM	14	1
Wei [62]	2006	31	37	WHO criteria	Shenfu In + BM + thrombolysis	BM + thrombolysis	7	0.25
Wu [63]	2006	19	21	WHO criteria	Shenmai In + BM	BM	20	1
Yang [64]	2006	48	49	Not reported	Xuezhikang capsules + BM	BM + placebo	N/A	72
Chen [65]	2007	30	30	WHO criteria	Tongxinluo capsule + BM	BM	56	2
Li [66]	2007	45	45	Author defined	Guanxinning In + BM	BM	15	6
Liang [67]	2007	90	68	WHO criteria	Shengmai In or Shenmai In + treatment based on TCM syndrome Differentiation + BM + thrombolysis	BM	N/A	N/A
Pan [68]	2007	20	20	WHO criteria	Tongxinluo capsule + BM	BM	N/A	1
Zhai [69]	2007	38	30	Criteria from Chinese Society of Cardiology	Shenmai In + BM	BM	10	N/A
Ding [70]	2008	23	23	Author defined	Shengmai In + BM	BM	N/A	N/A
Lan [71]	2008	130	128	WHO criteria	Xinmaitong capsules + BM	BM	30	1
Yu [72]	2008	100	96	Author defined	Shexiang Baoxin tablets + BM	BM	10	1
Yu [73]	2008	32	32	Author defined	Yinxingdamo In + BM + thrombolysis	BM + thrombolysis	14	0.5
Zhang [74]	2008	27	27	WHO criteria	Shenmai In + Shuxuening In + BM	BM	28	N/A
Gao [75]	2009	60	60	WHO criteria	Danhong In + BM	BM	N/A	0.5
Lin [76]	2009	25	25	Author defined	Compound danshen dripping pills + BM	BM	N/A	1
Liu [77]	2009	16	16	Author defined	Tanshinone II A sulfoacid In + BM	BM	7	3
Song [78]	2009	36	34	Author defined	Tongxinluo capsule + Shenmai In + Gegensu In + BM	BM	28	N/A
Yuan [79]	2009	38	38	WHO criteria	Shenmai In + thrombolysis	Thrombolysis	10	1
Zhao [80]	2009	50	48	Not reported	Tongxinluo capsule + BM + thrombolysis	BM + thrombolysis	N/A	12
Zuo [81]	2009	80	80	Criteria from Chinese Society of Cardiology	Breviscapinun + BM	BM	14	1
Guo [82]	2010	48	45	Not reported	Compound Danshen tablet + BM	BM	N/A	12
Xu [83]	2010	32	30	Author defined	Treatment based on TCM syndrome differentiation + BM	BM	28	1

BM: routine biomedical treatment as defined by the investigators; In: injection; N/A: not reported.

*Two RCTs reported in one publication.